235 related articles for article (PubMed ID: 419965)
1. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
Laatikainen T; Nieminen U; Adlercreutz H
Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
[TBL] [Abstract][Full Text] [Related]
2. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.
Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W
Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunoassay for medroxyprogesterone acetate (Provera) using the 11alpha-hydroxy succinyl conjugate.
Royer ME; Ko H; Campbell JA; Murray HC; Evans JS; Kaiser DG
Steroids; 1974 May; 23(5):713-30. PubMed ID: 4365969
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunoassays of ethinyl-norgestrienone (R-2323) and medroxyprogesterone acetate (MPA) and their clinical applicability.
Frick J; Bartsch G; Jakse G
Urol Res; 1977; 5(2):55-9. PubMed ID: 69351
[TBL] [Abstract][Full Text] [Related]
6. Treatment of breast cancer with medroxyprogesterone acetate.
Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunoassay for serum medroxyprogesterone acetate in Thai women receiving injectable DMPA contraceptive.
Werawatgoompa S; Pongpradit T; Leepipatpaiboon S; Sukanthanak A
Contraception; 1979 Oct; 20(4):319-27. PubMed ID: 509958
[TBL] [Abstract][Full Text] [Related]
8. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
[TBL] [Abstract][Full Text] [Related]
9. Unsuccessful treatment of acromegaly with medroxyprogesterone acetate.
Atkinson RL; Dimond RC; Howard WJ; Earll JM
Acta Endocrinol (Copenh); 1974 Sep; 77(1):19-25. PubMed ID: 4408390
[TBL] [Abstract][Full Text] [Related]
10. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of different doses of Depo Provera.
Fotherby K; Koetsawang S; Mathrubutham M
Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
[TBL] [Abstract][Full Text] [Related]
12. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
13. Medroxyprogesterone acetate (MPA) plasma levels after oral and intramuscular administration in a long-term study.
Hesselius I; Johansson ED
Acta Obstet Gynecol Scand Suppl; 1981; 101():65-70. PubMed ID: 6795891
[TBL] [Abstract][Full Text] [Related]
14. Progestogen treatment of recurrent endometrial carcinoma.
Malkasian GD; Decker DG; Mussey E; Johnson CE
Am J Obstet Gynecol; 1971 May; 110(1):15-23. PubMed ID: 5573604
[TBL] [Abstract][Full Text] [Related]
15. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
de Greef WJ; Dullaart J; Zeilmaker GH
J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
[TBL] [Abstract][Full Text] [Related]
16. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
17. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.
Cuna GR; Calciati A; Strada MR; Bumma C; Campio L
Tumori; 1978 Apr; 64(2):143-9. PubMed ID: 354147
[TBL] [Abstract][Full Text] [Related]
18. Sustained effects on synthetic ovarian steroids of rat myometrial contractility.
Parkington HC; Lipton A
J Endocrinol; 1976 Aug; 70(2):223-7. PubMed ID: 965882
[TBL] [Abstract][Full Text] [Related]
19. After-effect of injection.
Nelson M
Vet Rec; 1977 Jan; 100(4):78. PubMed ID: 835219
[TBL] [Abstract][Full Text] [Related]
20. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.
Ortiz A; Hirol M; Stanczyk FZ; Goebelsmann U; Mishell DR
J Clin Endocrinol Metab; 1977 Jan; 44(1):32-8. PubMed ID: 833262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
